IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference - IGC Pharma, INC.

Press

Releases

July 18, 2023

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

Related Posts

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease

December 2, 2025

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends

November 25, 2025

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

November 18, 2025

CEO Update

igc pharma

IGC Pharma, Inc. Form S-3 11-14-25

December 4, 2025

igc pharma

IGC Pharma, Inc. Form S-8 10-31-25

December 4, 2025